"Promising Biologic Ab-IPL-IL-17: A Breakthrough for Rheumatoid Arthritis and Inflammatory Bowel Disease"
Researchers have developed a novel antibody, Ab-IPL-IL-17, that targets a specific amino acid sequence in interleukin-17A and interleukin-17F, which play a crucial role in autoimmune diseases like rheumatoid arthritis and inflammatory bowel disease. The antibody has shown potent anti-inflammatory activity in animal and tissue studies, without triggering unwanted side effects. It is as effective as the current gold-standard treatment for rheumatoid arthritis in halting disease progression and triggering resolution. The researchers are seeking commercial partners for large-scale clinical evaluation of Ab-IPL-IL-17 in patients with immune-mediated inflammatory diseases.